Novartis AG
https://www.novartis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novartis AG
Secura’s Copiktra: Trial Design, Shifting Standard Of Care Could Spell The End For Third-Line CLL/SLL
In concluding benefits do not outweigh risks in the drug’s current indication, US FDA advisory committee members cite concerns about survival data from the Phase III DUO trial, as well as the drug’s toxicities, safety issues with the PI3K inhibitor class, and the changing treatment landscape for chronic lymphocytic leukemia and small lymphocytic lymphoma.
AstraZeneca Pulls Plug On Ionis’ PCSK9 Candidate
While the Phase IIb SOLANO trial of ION449 met its primary endpoint, AstraZeneca had set a high bar of 70% LDL cholesterol reduction for competitiveness that the study did not hit.
Leqvio Launch Will Be Fundamental To Success Of New Novartis
Discussion of the launch trajectory for the twice-yearly cholesterol therapy dominated the marketing portion of Novartis’s investor event and the firm is confident the foundations have been laid to push strong sales growth by the second half of next year.
New Pure Play Novartis Vows To Up Its Game – With Help From In-House Challenger Ronny Gal
Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Admune Therapeutics
- Amblyotech, Inc.
- Advanced Accelerator Applications SA (AAAP) (BioSynthema, Inc.)
- Aspen Japan K.K.
- Biocine
- CELLforCURE SASU
- Chiron Corporation
- CIBA-GEIGY
- Corthera Inc.
- CoStim Pharmaceuticals Inc.
- ESBATech AG
- Fougera Pharmaceuticals, Inc.
- Gyroscope Therapeutics Limited
- Hexal AG
- Lek Pharmaceuticals, Inc.
- Matrix Pharmaceuticals
- NeuTec Pharma
- Novartis Groupe France S.A.
- Novartis Pharmaceuticals
- Novartis Oncology
- Novogyne Pharmaceuticals (joint venture between Noven and Novartis)
- PowerVision, Inc.
- Protez Pharmaceuticals
- Sandoz Pharmaceuticals (Ever Neuro Pharma GmbH
- Ebewe Pharma)
- Selexys Pharmaceuticals Corporation
- Speedel Holding
- Spinifex Pharmaceuticals Pty. Ltd.
- Transcend Medical, Inc.
- Encore Vision, Inc.
- Ziarco Group Limited
- AveXis, Inc.
- BioLife Cell Bank, Inc.
- Endocyte, Inc.
- IFM Tre
- Zyma SA
- Annovation Biopharma, Inc.
- Boxford Subsidiary
- Curacyte Discovery GmbH
- Incline Therapeutics, Inc.
- ProFibrix B.V.
- Rempex Pharmaceuticals, Inc.
- Targanta Therapeutics Corporation
- Tenaxis Medical
- The Medicines Company
- Novartis Gene Therapies